Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
by
Skoreński, Marcin
, Sieńczyk, Marcin
in
antivirals
/ Drugs
/ enzyme inhibitors
/ Enzymes
/ FDA approval
/ Mutation
/ Pain
/ privileged structures
/ Review
/ RNA polymerase
2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
by
Skoreński, Marcin
, Sieńczyk, Marcin
in
antivirals
/ Drugs
/ enzyme inhibitors
/ Enzymes
/ FDA approval
/ Mutation
/ Pain
/ privileged structures
/ Review
/ RNA polymerase
2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
Journal Article
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
2021
Request Book From Autostore
and Choose the Collection Method
Overview
Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents.
This website uses cookies to ensure you get the best experience on our website.